Yue Liao

Yue Liao

Auto-generated profile, based on publicly available information

Yue Liao

Department of Pharmacy, Chongqing General Hospital, Chongqing University, Chongqing, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in Clinics
Verified
Journal Article
Open access
YLYue Liao
Yue Liao
QYQilin Yang
Qilin Yang
DLDaxue Li
Daxue Li
YWYulong Wang
Yulong Wang
Previous studies have indicated that perioperative serum haptoglobin levels are associated with the risk of Acute Kidney Injury (AKI). However, the relationship between haptoglobin and AKI in sepsis patients remains unclear. This study aimed to investigate the association between serum haptoglobin levels and AKI in critically ill sepsis patients. The authors conducted a retrospective cohort study using data extracted from the Medical Information Mart for the Intensive Care (MIMIC) IV database version 3.0. Multivariable logistic regression analysis was used to control for potential confounders. Curve fitting was performed to assess the linearity of the association, and subgroup analyses were conducted to validate the robustness of the findings. This study included 1324 participants (mean age 64.7 ± 17.6 years; 53.8 % male). The fully adjusted model showed an inverse association between serum haptoglobin levels and AKI. Each 10 mg/dL increase in haptoglobin decreased AKI odds by 1.4 % (OR = 0.986, 95 % CI 0.973‒0.999, p = 0.037). Patients in the highest haptoglobin group had 34.5 % lower AKI risk versus the lowest group (OR = 0.655, 95 % CI 0.439‒0.976, p = 0.038). The linear relationship (p for non-linearity = 0.152) remained robust in subgroup analyses. The present findings suggest that elevated serum haptoglobin levels may serve as a protective factor against AKI in critically ill sepsis patients. Nevertheless, prospective, randomized, controlled studies are required to confirm the findings presented in this investigation.

30 December 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YLYue Liao
Yue Liao
YWYulong Wang
Yulong Wang
DLDaxue Li
Daxue Li
XQXuewen Qiu
Xuewen Qiu
Background: Acetaminophen serves as a standard antipyretic and analgesic agent in the intensive care unit (ICU). However, the association between its administration and acute kidney injury (AKI) among critically ill patients remains controversial, particularly lacking research in patients with Clostridioides difficile infection (CDI). Our aim was to explore the potential relationship between early acetaminophen administration and AKI in critically ill patients with concurrent CDI. Methods: Using data from the Medical Information Mart for Intensive Care (MIMIC) IV version 2.2 database, we performed a retrospective cohort study. AKI within 7 days of ICU admission was the main outcome that was measured. We utilized multivariable logistic regression models adjusted for potential confounders based on statistical significance and clinical relevance, to investigate the association between acetaminophen exposure and the risk of AKI in patients with CDI. Additionally, subgroup analyses and sensitivity analysis were conducted to assess the robustness of our primary findings. Results: The average age of 984 participants was 66.8 ± 16.5 years, and 52.7% (519) were male. The overall proportion of patients who developed AKI was 75.4% (742/984). In patients without and with acetaminophen administration, AKI rates were 79.8% (380/476) and 71.3% (362/508), respectively. Compared to the non-acetaminophen administration group, the risk of AKI was lower in the acetaminophen administration group (absolute risk difference: -8.5%, 95%CI: -13.83%∼-3.17%, P < 0.01).After adjusting for potential confounders, acetaminophen administration was associated with a 32% reduction in the risk of AKI (OR = 0.68, 95%CI:0.48∼0.96, P = 0.027). Conclusion: Our study suggests that early acetaminophen administration may offer renal protection by reducing the risk of AKI in critically ill patients with CDI. Prospective, multicenter randomized controlled studies are needed to verify this finding.